COLL
NASDAQCollegium Pharmaceutical Inc.
News · 26 weeks51+250%
2026-03-012026-08-23
Mix1490d
- SEC Filings6(43%)
- Other5(36%)
- Earnings2(14%)
- Insider1(7%)
Latest news
25 items- SECSEC Form SCHEDULE 13G filed by Collegium Pharmaceutical Inc.SCHEDULE 13G - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Subject)
- SECSEC Form 8-K filed by Collegium Pharmaceutical Inc.8-K - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Filer)
- PRCollegium Announces $50 Million Accelerated Share Repurchase ProgramSTOUGHTON, Mass., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL), a leading biopharmaceutical company focused on improving the lives of people living with serious and often misunderstood conditions, today announced that it has entered into an Accelerated Share Repurchase ("ASR") agreement with Jefferies LLC to repurchase $50 million of the Company’s common stock. Collegium will execute the ASR as part of the $150 million share repurchase program authorized by its Board of Directors in July 2025. Upon completion of this ASR, Collegium will have $100 million remaining under the program. "Collegium’s strong financial position, rapidly growing ADHD portfolio an
- SECSEC Form 10-Q filed by Collegium Pharmaceutical Inc.10-Q - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Filer)
- SECCollegium Pharmaceutical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Filer)
- PRCollegium Reports Second Quarter 2026 Financial Results and Highlights Recent Company Progress– Completed Acquisition of AZSTARYS®, Strengthening ADHD Portfolio and Extending Long-Term Revenue Outlook – – Generated Quarterly Net Revenues of $199.9 Million, Up 6% Year-over-Year – – Generated JORNAY PM® Quarterly Net Revenue of $46.1 Million, Up 41% Year-over-Year – – Generated AZSTARYS Quarterly Net Revenue of $12.9 Million, Representing a Partial Quarter of Sales – – Generated Quarterly Pain Portfolio Net Revenues of $140.9 Million – – Updates Full-Year 2026 Financial Guidance – – Conference Call Scheduled for Today at 8:00 a.m. ET – STOUGHTON, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL), a leading biopharmaceutical company focused
- SECSEC Form SCHEDULE 13G filed by Collegium Pharmaceutical Inc.SCHEDULE 13G - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Subject)
- PRCollegium to Report Second Quarter 2026 Financial Results on August 6, 2026STOUGHTON, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL), a leading biopharmaceutical company focused on improving the lives of people living with serious and often misunderstood conditions, today announced that it will report second quarter 2026 financial results before the market opens on Thursday August 6, 2026. Following the release of the financials, the Company will host a live conference call and webcast at 8:00 a.m. ET. Conference Call Information To access the conference call, please dial (877) 407-8037 (U.S.) or (201) 689-8037 (International) and reference the "Collegium Pharmaceutical Q2 2026 Earnings Call." An audio webcast will be acces
- PRCollegium Pharmaceutical Announces New Corporate Headquarters at One Lincoln in BostonSTOUGHTON, Mass., July 20, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL) a leading biopharmaceutical company focused on improving the lives of people living with serious and often misunderstood conditions, today announced plans to relocate its corporate headquarters to One Lincoln in downtown Boston in the first quarter of 2027. The decision reflects Collegium's continued evolution as a diversified biopharmaceutical company. Located in the heart of Boston, One Lincoln places Collegium within one of the world's leading healthcare and life sciences ecosystems, creating greater opportunities to engage with the scientific, academic, healthcare and business communities
- SECAmendment: Collegium Pharmaceutical Inc. filed SEC Form 8-K: Financial Statements and Exhibits8-K/A - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Filer)
- INSIDERDirector Santini Gino exercised 8,700 shares at a strike of $16.49, increasing direct ownership by 8% to 112,483 units (SEC Form 4)4 - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Issuer)
- PRCollegium Pharmaceutical Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)STOUGHTON, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL) today announced it awarded inducement grants on June 1, 2026 under the Company's 2026 Inducement Plan (the 2026 Inducement Plan). The Company granted 50,305 restricted stock units (RSUs), in aggregate, as a material inducement to the employment of 34 non-executive individuals newly hired by the Company. Each RSU represents a contingent right to receive one share of the Company's common stock. One-third of the RSUs shall vest on June 10, 2027, with the balance of the RSUs vesting in equal annual installments over the following two-year period, subject to the employee's continued service with th
- SECSEC Form S-8 filed by Collegium Pharmaceutical Inc.S-8 - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Filer)
- SECSEC Form S-8 filed by Collegium Pharmaceutical Inc.S-8 - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Filer)
- PRCollegium to Participate in 2026 Jefferies Global Healthcare ConferenceSTOUGHTON, Mass., May 27, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL) today announced that its management will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference. Details of the event are as follows: Fireside Chat Date and Time: Wednesday, June 3, 2026, at 1:20 p.m. ETNew York, NY A live webcast of the fireside chat will be available via the Investors section of the Company's website: https://ir.collegiumpharma.com. A replay of the webcast will be archived on the Company's website for 90 days following the presentation. About Collegium Pharmaceutical, Inc.Collegium Pharmaceutical is a dynamic, biopharmaceutical company delivering
- INSIDERDirector Freund John Gordon sold $681 worth of shares (20 units at $34.05), decreasing direct ownership by 0.02% to 83,952 units (SEC Form 4)4 - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Issuer)
- INSIDERDirector Bohlin Garen G was granted 8,741 shares, increasing direct ownership by 14% to 71,000 units (SEC Form 4)4 - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Issuer)
- INSIDERDirector Freund John Gordon was granted 8,741 shares, exercised 8,700 shares at a strike of $16.49 and sold $142,547 worth of shares (4,127 units at $34.54), increasing direct ownership by 19% to 83,972 units (SEC Form 4)4 - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Issuer)
- INSIDERDirector Paya Carlos V was granted 8,741 shares, increasing direct ownership by 45% to 28,323 units (SEC Form 4)4 - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Issuer)
- INSIDERDirector Lurker Nancy was granted 8,741 shares, increasing direct ownership by 49% to 26,758 units (SEC Form 4)4 - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Issuer)
- INSIDERDirector Balice-Gordon Rita J. was granted 8,741 shares, increasing direct ownership by 17% to 61,370 units (SEC Form 4)4 - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Issuer)
- INSIDERDirector Glancy Donovan Michael was granted 17,482 shares (SEC Form 4)4 - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Issuer)
- INSIDERDirector Santini Gino was granted 8,741 shares, increasing direct ownership by 9% to 103,783 units (SEC Form 4)4 - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Issuer)
- INSIDERSEC Form 3 filed by new insider Glancy Donovan Michael3 - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Issuer)
- SECCollegium Pharmaceutical Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Filer)
COLL FAQ
7 questionsWhat does Collegium Pharmaceutical Inc. do?
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003...Where does COLL stock trade?
Collegium Pharmaceutical Inc. (COLL) is listed on NASDAQ.What sector and industry is COLL in?
Collegium Pharmaceutical Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Collegium Pharmaceutical Inc. go public?
Collegium Pharmaceutical Inc. (COLL) completed its IPO in 2015.What are analysts saying about COLL?
Collegium Pharmaceutical Inc. has had 8 recent analyst actions on file. The most recent action was from Barclays: Overweight on 2025-12-09. Recent price targets range from $3600.00 to $4700.00.What companies are similar to COLL?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare COLL side-by-side with any of them on Quantisnow.How can I track COLL on Quantisnow?
Quantisnow aggregates Collegium Pharmaceutical Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow COLL to receive live email and push alerts on every new disclosure.